[go: up one dir, main page]

NO20083114L - Polysykliske indazolderivater som er ERK-inhibitorer - Google Patents

Polysykliske indazolderivater som er ERK-inhibitorer

Info

Publication number
NO20083114L
NO20083114L NO20083114A NO20083114A NO20083114L NO 20083114 L NO20083114 L NO 20083114L NO 20083114 A NO20083114 A NO 20083114A NO 20083114 A NO20083114 A NO 20083114A NO 20083114 L NO20083114 L NO 20083114L
Authority
NO
Norway
Prior art keywords
erk inhibitors
indazole derivatives
ring
polycyclic
formula
Prior art date
Application number
NO20083114A
Other languages
English (en)
Other versions
NO341831B1 (no
Inventor
Alan Bruce Cooper
Vincent Stewart Madison
James J S Wang
Ronald J Doll
Hugh Y Zhu
Jagdish A Desai
Hon-Chung Tsui
Neng-Yang Shih
Li Xiao
Sunil Paliwal
M Arshad Siddiqui
Yongqi Deng
Jr Gerald W Shipps
Robert Sun
Joseph Kelly
Yang Nan
Tong Wang
Youhao Dong
Alan Hruza
Ahmed Samatar
Original Assignee
Uswu Yiji
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Uswu Yiji filed Critical Uswu Yiji
Publication of NO20083114L publication Critical patent/NO20083114L/no
Publication of NO341831B1 publication Critical patent/NO341831B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

Det beskrives ERK-inhibitorer med formel 1.0: og farmasøytisk akseptable salter og solvater derav. Q er en piperidin-eller piperazinring som kan ha en hydrogenbinding eller en kondensert ring. Piperidinringen kan ha en dobbeltbinding i ringen. Alle andre substituenter er som definert her. Det beskrives også anvendelse av forbindelsene med formel 1.0 til behandling av cancer.
NO20083114A 2005-12-13 2008-07-11 Polysykliske indazolderivater som er ERK-inhibitorer, farmasøytisk preparat derav og anvendelse derav for fremstilling av et medikament NO341831B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US74985605P 2005-12-13 2005-12-13
PCT/US2006/046959 WO2007070398A1 (en) 2005-12-13 2006-12-11 Polycyclic indazole derivatives that are erk inhibitors

Publications (2)

Publication Number Publication Date
NO20083114L true NO20083114L (no) 2008-09-12
NO341831B1 NO341831B1 (no) 2018-01-29

Family

ID=37969564

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20083114A NO341831B1 (no) 2005-12-13 2008-07-11 Polysykliske indazolderivater som er ERK-inhibitorer, farmasøytisk preparat derav og anvendelse derav for fremstilling av et medikament

Country Status (28)

Country Link
US (1) US20070191604A1 (no)
EP (1) EP1966151B1 (no)
JP (1) JP4881957B2 (no)
KR (1) KR101417136B1 (no)
CN (1) CN101370784B (no)
AR (1) AR056891A1 (no)
AT (1) ATE527240T1 (no)
AU (1) AU2006326616B2 (no)
BR (1) BRPI0619823B8 (no)
CA (1) CA2633023C (no)
CY (1) CY1112760T1 (no)
DK (1) DK1966151T3 (no)
EC (1) ECSP088550A (no)
ES (1) ES2372976T3 (no)
HR (1) HRP20110892T1 (no)
IL (1) IL192034A (no)
MY (1) MY149430A (no)
NO (1) NO341831B1 (no)
NZ (1) NZ569087A (no)
PE (2) PE20100562A1 (no)
PL (1) PL1966151T3 (no)
PT (1) PT1966151E (no)
RS (1) RS51981B (no)
RU (1) RU2442778C9 (no)
SI (1) SI1966151T1 (no)
TW (1) TWI344466B (no)
WO (1) WO2007070398A1 (no)
ZA (1) ZA200805525B (no)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8546404B2 (en) * 2005-12-13 2013-10-01 Merck Sharp & Dohme Compounds that are ERK inhibitors
WO2007097937A1 (en) * 2006-02-16 2007-08-30 Schering Corporation Pyrrolidine derivatives as erk inhibitors
JP2009542666A (ja) 2006-06-30 2009-12-03 シェーリング コーポレイション Ｐ５３活性を増加させる置換ピペリジンおよびその使用
TW200911262A (en) * 2007-06-05 2009-03-16 Schering Corp Novel compounds that are ERK inhibitors
AR067354A1 (es) * 2007-06-29 2009-10-07 Sunesis Pharmaceuticals Inc Compuestos utiles como inhibidores de la raf quinasa
MX2010005960A (es) * 2007-11-30 2010-06-11 Schering Corp Biomarcadores de braf.
WO2009105500A1 (en) * 2008-02-21 2009-08-27 Schering Corporation Compounds that are erk inhibitors
KR20100117686A (ko) * 2008-02-29 2010-11-03 어레이 바이오파마 인크. 피라졸[3,4-ｂ]피리딘 ｒａｆ 저해물질
WO2009137649A2 (en) * 2008-05-07 2009-11-12 The Trustees Of The University Of Pennsylvania Methods for treating thyroid cancer
WO2010021978A2 (en) * 2008-08-19 2010-02-25 Schering Corporation Il-8 biomarker
US9229008B2 (en) 2008-08-19 2016-01-05 Merck Sharp & Dohme Corp. IL-8 level as a determinant of responsivity of a cancer to treatment
US8609675B2 (en) 2009-07-02 2013-12-17 Merck Sharp & Dohme Corp. Fused Tricyclic Compounds as novel mTOR inhibitors
WO2011041152A1 (en) 2009-09-30 2011-04-07 Schering Corporation Novel compounds that are erk inhibitors
AU2010307198B9 (en) 2009-10-14 2014-02-13 Merck Sharp & Dohme Corp. Substituted piperidines that increase p53 activity and the uses thereof
WO2011123937A1 (en) * 2010-04-06 2011-10-13 University Health Network Kinase inhibitors and method of treating cancer with same
US8999957B2 (en) 2010-06-24 2015-04-07 Merck Sharp & Dohme Corp. Heterocyclic compounds as ERK inhibitors
WO2012015932A2 (en) * 2010-07-27 2012-02-02 Protexer, Inc. Shoe cover removal apparatus
WO2012027236A1 (en) 2010-08-23 2012-03-01 Schering Corporation NOVEL PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS
EP2613782B1 (en) * 2010-09-01 2016-11-02 Merck Sharp & Dohme Corp. Indazole derivatives useful as erk inhibitors
WO2012078777A1 (en) * 2010-12-09 2012-06-14 Amgen Inc. Bicyclic compounds as pim inhibitors
EP2654748B1 (en) 2010-12-21 2016-07-27 Merck Sharp & Dohme Corp. Indazole derivatives useful as erk inhibitors
WO2012129338A1 (en) 2011-03-22 2012-09-27 Amgen Inc. Azole compounds as pim inhibitors
WO2012143879A1 (en) 2011-04-21 2012-10-26 Piramal Healthcare Limited A crystalline form of a salt of a morpholino sulfonyl indole derivative and a process for its preparation
WO2013016164A1 (en) 2011-07-26 2013-01-31 Merck Sharp & Dohme Corp. FUSED TRICYCLIC COMPOUNDS AS mTOR INHIBITORS
EP2771008A4 (en) 2011-10-28 2015-04-08 Merck Sharp & Dohme MACROCYCLES FOR INCREASING P53 ACTIVITY AND USES THEREOF
WO2013096150A1 (en) 2011-12-21 2013-06-27 Merck Sharp & Dohme Corp. Substituted piperidines as hdm2 inhibitors
WO2013109142A1 (en) 2012-01-16 2013-07-25 Stichting Het Nederlands Kanker Instituut Combined pdk and mapk/erk pathway inhibition in neoplasia
ITMI20120135A1 (it) * 2012-02-02 2013-08-03 Diab Int Ab Procedimento per la produzione di schiume di pet e schiume di pet ottenute con questo procedimento
WO2013169858A1 (en) 2012-05-08 2013-11-14 The Broad Institute, Inc. Diagnostic and treatment methods in patients having or at risk of developing resistance to cancer therapy
CN103450163B (zh) * 2012-05-29 2017-06-23 中国医学科学院药物研究所 吲唑类化合物、其制备方法及其药物用途
IN2015DN01328A (no) 2012-09-19 2015-07-03 Novartis Ag
AU2013323508B2 (en) * 2012-09-28 2017-11-02 Merck Sharp & Dohme Corp. Novel compounds that are ERK inhibitors
WO2014100065A1 (en) 2012-12-20 2014-06-26 Merck Sharp & Dohme Corp. Substituted imidazopyridines as hdm2 inhibitors
WO2015041533A1 (en) 2013-09-20 2015-03-26 Stichting Het Nederlands Kanker Instituut Rock in combination with mapk-pathway
WO2015041534A1 (en) 2013-09-20 2015-03-26 Stichting Het Nederlands Kanker Instituut P90rsk in combination with raf/erk/mek
CA2922532C (en) 2013-11-01 2023-09-19 Novartis Ag Aminoheteroaryl benzamides as kinase inhibitors
US20170027940A1 (en) 2014-04-10 2017-02-02 Stichting Het Nederlands Kanker Instituut Method for treating cancer
WO2015178770A1 (en) 2014-05-19 2015-11-26 Stichting Het Nederlands Kanker Instituut Compositions for cancer treatment
WO2016095088A1 (en) * 2014-12-15 2016-06-23 Merck Sharp & Dohme Corp. Erk inhibitors
WO2016095089A1 (en) * 2014-12-15 2016-06-23 Merck Sharp & Dohme Corp. Erk inhibitors
US10864179B2 (en) 2015-10-01 2020-12-15 Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Histone deacetylase inhibitors for the use in the treatment of drug resistant melanoma
IL291017B2 (en) 2015-10-21 2023-11-01 Otsuka Pharma Co Ltd Benzolactam compounds as protein kinase inhibitors
WO2017099591A1 (en) 2015-12-07 2017-06-15 Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Treatment of inhibitor resistant braf-mutant cancers
CN115746000A (zh) * 2016-03-11 2023-03-07 嘉兴和剂药业有限公司 用于调节布鲁顿酪氨酸激酶的化合物及方法
WO2017204626A1 (en) 2016-05-24 2017-11-30 Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Combination therapy - combined map2k4/map3k1 and mek/erk inhibition
AU2017339890A1 (en) 2016-10-05 2019-04-11 Recurium Ip Holdings, Llc Spirocyclic compounds
GB201706327D0 (en) 2017-04-20 2017-06-07 Otsuka Pharma Co Ltd A pharmaceutical compound
CA3090842A1 (en) 2018-03-12 2019-09-19 Abbvie Inc. Inhibitors of tyrosine kinase 2 mediated signaling
CN114605329B (zh) * 2022-03-28 2024-01-26 河南中医药大学 取代的吲唑甲酰胺或取代的氮杂吲唑甲酰胺类flt3抑制剂及其用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9213077D0 (en) 1992-06-19 1992-08-05 Erba Carlo Spa Polymerbound taxol derivatives
CN1362953A (zh) * 2000-02-05 2002-08-07 沃泰克斯药物股份有限公司 用作erk抑制剂的吡唑组合物
US6897231B2 (en) * 2000-07-31 2005-05-24 Signal Pharmaceuticals, Inc. Indazole derivatives as JNK inhibitors and compositions and methods related thereto
MY130778A (en) * 2001-02-09 2007-07-31 Vertex Pharma Heterocyclic inhibitiors of erk2 and uses thereof
BR0314098A (pt) * 2002-09-05 2005-07-19 Aventis Pharma Sa Derivados da aminoindazóis a tìtulo de medicamentos e composições farmacêuticas que os contêm

Also Published As

Publication number Publication date
BRPI0619823B1 (pt) 2020-11-17
RS51981B (sr) 2012-02-29
NZ569087A (en) 2011-09-30
RU2442778C9 (ru) 2012-08-10
NO341831B1 (no) 2018-01-29
ATE527240T1 (de) 2011-10-15
AR056891A1 (es) 2007-10-31
CN101370784B (zh) 2012-10-10
ZA200805525B (en) 2009-11-25
ES2372976T3 (es) 2012-01-30
KR20080085018A (ko) 2008-09-22
JP4881957B2 (ja) 2012-02-22
CN101370784A (zh) 2009-02-18
JP2009519338A (ja) 2009-05-14
RU2008128119A (ru) 2010-01-20
AU2006326616B2 (en) 2012-09-06
PT1966151E (pt) 2011-12-20
AU2006326616A1 (en) 2007-06-21
PL1966151T3 (pl) 2012-02-29
CA2633023C (en) 2015-11-24
KR101417136B1 (ko) 2014-08-07
BRPI0619823A8 (pt) 2019-01-22
TW200732324A (en) 2007-09-01
TWI344466B (en) 2011-07-01
IL192034A0 (en) 2008-12-29
BRPI0619823A2 (pt) 2011-11-08
BRPI0619823B8 (pt) 2021-05-25
HK1114851A1 (en) 2008-11-14
EP1966151A1 (en) 2008-09-10
HRP20110892T1 (hr) 2011-12-31
WO2007070398A1 (en) 2007-06-21
ECSP088550A (es) 2008-07-30
MY149430A (en) 2013-08-30
PE20071095A1 (es) 2007-11-19
US20070191604A1 (en) 2007-08-16
PE20100562A1 (es) 2010-08-20
SI1966151T1 (sl) 2012-02-29
EP1966151B1 (en) 2011-10-05
CA2633023A1 (en) 2007-06-21
IL192034A (en) 2014-08-31
RU2442778C2 (ru) 2012-02-20
CY1112760T1 (el) 2016-02-10
DK1966151T3 (da) 2012-01-30

Similar Documents

Publication Publication Date Title
NO20083114L (no) Polysykliske indazolderivater som er ERK-inhibitorer
NO20054852L (no) GFAT inhibitorer
NO20061454L (no) Compounds having CRTH2 antagonist activity
NO20044866L (no) Pyrazolo-pyrimidin-anilin-forbindelser anvendelige som kinase-inhibitorer
NO20071137L (no) Nye piperidinderivater for behandling av depresjon
NO20071617L (no) Indozolonderivater som 11B-HSD1-inhibitorer
NO20082388L (no) Heteroaryl substituerte piperidinderivater som L-CPT1 inhibitorer
NO20051600L (no) 1,4-disubstituerte piperidinderivater og anvendelse derav som 11-betaHSD1 inhibitorer
NO20062692L (no) Heterosykliske MEK inhibitorer og fremgangsmater for anvendelse derav
NO20075059L (no) Nye forbindelser II 2-pyridinderivater som inhibitorer av neutrofil elastase
NO20070445L (no) Pyrimidinderivater.
NO20082496L (no) Pyrazinderivater
NO20081315L (no) Benzokinazolinderivater og deres anvendelse ved behandling av benlidelser
NO20076066L (no) Oksadiazolderivater som DGAT-inhibitorer
NO20050828L (no) lndol-3-svovelderivater
PT1940839E (pt) Inibidores de piridopirimidinona pi3k alfa
NO20073791L (no) Pyrazolylaminopyridinderivater anvendbare som kinaseinhibitorer
NO20092033L (no) Nye forbindelser
NO20070458L (no) Aryl-pyridinderivater som 11-Beta-HSD1 inhibitorer
NO20076695L (no) Nye MCHR1-antagonister og deres anvendelse for behandling av MCHR1-medierte tilstander og forstyrrelser
NO20091590L (no) Heterocykliske amidforbindelser anvendbare som kinaseinhibitorer
NO20064282L (no) Morfolinforbindelser
IS2696B (is) Setin 2-amínótetralín fyrir meðhöndlunina á geðdeyfð
GB0314967D0 (en) Piperazine derivatives
NO20092035L (no) Tiazolylforbindelser anvendbare som kinaseinhibitorer

Legal Events

Date Code Title Description
CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: MERCK SHARP AND DOHME CORP, US

Free format text: NEW ADDRESS: 126 EAST LINCOLN AVENUE, US-NJ07065 RAHWAY

MM1K Lapsed by not paying the annual fees